Shares of Verona Pharma plc (NASDAQ:TARA) have earned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.

Brokers have set a twelve-month consensus target price of $45.00 for the company, according to Zacks. Zacks has also assigned Verona Pharma an industry rank of 85 out of 254 based on the ratings given to related companies.

A number of analysts have recently issued reports on the company. ValuEngine lowered Verona Pharma from a “buy” rating to a “hold” rating in a report on Monday, March 30th. Zacks Investment Research raised Verona Pharma from a “sell” rating to a “hold” rating in a research note on Wednesday, June 24th.

Institutional investors and hedge funds have recently bought and sold shares of the company. Victory Capital Management Inc. acquired a new stake in shares of Verona Pharma during the 4th quarter valued at about $32,000. Citigroup Inc. bought a new position in Verona Pharma during the first quarter valued at approximately $43,000. DRW Securities LLC bought a new stake in Verona Pharma in the first quarter worth approximately $3,071,000. Ikarian Capital LLC acquired a new position in shares of Verona Pharma during the 1st quarter worth $10,368,000. Finally, Perceptive Advisors LLC bought a new position in shares of Verona Pharma during the 1st quarter valued at $184,000. 67.70% of the stock is owned by institutional investors.

TARA traded down $2.19 during trading on Wednesday, reaching $27.50. The company had a trading volume of 4,978 shares, compared to its average volume of 43,141. Verona Pharma has a 12-month low of $8.80 and a 12-month high of $67.08. The company has a 50-day moving average of $36.41.

Verona Pharma (NASDAQ:TARA) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($1.81) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($1.40). Equities analysts anticipate that Verona Pharma will post -2.59 EPS for the current year.

Verona Pharma Company Profile

ArTara Therapeutics, Inc develops rare diseases therapeutics for patients suffering from gastrointestinal, metabolic, circulatory, and neurological disorders. It offers IV Choline Chloride, a drug for the orphan disease intestinal failure associated liver disease (IFALD). The company was incorporated in 2017 and is headquartered in New York, New York.

Further Reading: The Role of a Fiduciary and Individual Investors

Get a free copy of the Zacks research report on Verona Pharma (TARA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with's FREE daily email newsletter.